Latanoprost Actavis

Latanoprost, the active ingredient in Latanoprost Actavis, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular administration. It is indicated for the reduction of intra‑ocular pressure in primary open‑angle glaucoma and ocular hypertension, primarily in adult patients.

GNH USA supplies Latanoprost Actavis as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. The company ensures quality control, regulatory compliance, and reliable global logistics for this prescription‑only medication.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Pseudoexfoliative glaucoma: decreases pressure to protect the optic nerve. - Pigmentary glaucoma: helps control intra‑ocular pressure and preserve visual function.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Increased iris pigmentation: gradual darkening of the iris color. - Eyelash changes: longer, thicker, or darker eyelashes. - Eye redness: mild conjunctival hyperemia. - Eye irritation: transient burning or stinging after instillation.

Serious or Rare Side Effects: - Severe allergic reaction: conjunctivitis or swelling of the eyelids. - Corneal edema: swelling of the cornea that can impair vision. - Macular edema: fluid accumulation in the central retina, potentially reducing visual acuity.

Before using Latanoprost, consider the following precautions.

- Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown safety; weigh potential risks and benefits. - Contraindications: do not use in eyes with active inflammation or infection. - Monitoring: intra‑ocular pressure should be measured regularly after initiation. - Contact lens wearers: may experience deposits; consider removing lenses before application. - Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents.

Major Interactions (Avoid): - Prostaglandin analogs (e.g., bimatoprost): additive ocular effects. - Systemic carbonic anhydrase inhibitors: may reduce IOP‑lowering efficacy. - Non‑steroidal anti‑inflammatory eye drops: increased risk of ocular inflammation.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: possible additive intra‑ocular pressure reduction. - Topical corticosteroids: may diminish Latanoprost’s IOP‑lowering effect. - Anticholinergic eye drops: monitor for changes in ocular surface health.